Poorly differentiated neuroendocrine carcinomas of the gastrointestinal tract: A single-institute study of 43 cases

被引:6
作者
Chen, Irene [1 ]
Zhang, Dongwei [1 ]
Velez, Moises [1 ]
Kovar, Sierra [1 ]
Liao, Xiaoyan [1 ]
机构
[1] Univ Rochester, Med Ctr, Dept Pathol & Lab Med, Rochester, NY 14642 USA
关键词
Neuroendocrine carcinoma; INSM1; SATB2; PD-L1; Prognosis; PD-L1; EXPRESSION; CANCER; COLON;
D O I
10.1016/j.prp.2021.153614
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Objectives: To characterize the clinicopathologic and immunohistochemical features of poorly differentiated neuroendocrine carcinomas (NEC) in the gastrointestinal tract. Design: A total of 43 cases were identified and reassessed based on modern classification. Results: The cohort (27M, 16F; median age: 66 years) included 16 (37%) large cell NEC, 12 (28%) small cell NEC, 5 (12%) NEC not otherwise specified, and 10 (23%) mixed adenoneuroendocrine carcinomas. Tumor predominantly involved the colon (n = 14, 33%), rectum (n = 13, 30%), and esophagus (n = 9, 21%). Immunohistochemically, INSM1 was the most sensitive marker for neuroendocrine differentiation (28/28, 100%), followed by synaptophysin (40/43, 93%), CD56 (22/35, 63%), and chromogranin (18/40, 45%). SATB2, CDX2, CK20, CK7, abnormal p53, and PD-L1 was positive in 21/26 (81%), 26/37 (70%), 11/35 (31%), 10/35 (29%), 19/24 (79%), and 12/23 (52%) cases, respectively. Three of 25 (11%) were mismatch repair protein deficient. Of 21 resected tumors, 19 (90%) were >= pT3 and 13 (62%) had nodal metastasis. Twenty-eight (65%) had distant metastasis. The 5-year survival rate was 21%. The prognosis was stage dependent (p < 0.05), but not associated with tumor type, location, or specific immunomarkers. Conclusion: Gastrointestinal NECs are aggressive neoplasms. INSM1, synaptophysin, and SATB2 are sensitive markers, although not site or tumor type specific.
引用
收藏
页数:7
相关论文
共 50 条
  • [11] Quantitative analysis of enhanced CT in differentiating well-differentiated pancreatic neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas
    Hai-Yan Chen
    Yao Pan
    Jie-Yu Chen
    Lu-lu Liu
    Yong-Bo Yang
    Kai Li
    Ri-Sheng Yu
    Guo-Liang Shao
    European Radiology, 2022, 32 : 8317 - 8325
  • [12] Feasibility and Efficacy of Combined Cisplatin and Irinotecan Chemotherapy for Poorly Differentiated Neuroendocrine Carcinomas
    Nakano, Kenji
    Takahashi, Shunji
    Yuasa, Takeshi
    Nishimura, Noriko
    Mishima, Yuko
    Sakajiri, Sakura
    Yokoyama, Masahiro
    Tsuyama, Naoko
    Ishikawa, Yuichi
    Hatake, Kiyohiko
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 42 (08) : 697 - 703
  • [13] Comprehensive analysis of mutational and clinicopathologic characteristics of poorly differentiated colorectal neuroendocrine carcinomas
    Lee, Sun Mi
    Sung, Chang Ohk
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [14] High-Grade Poorly Differentiated Neuroendocrine Carcinomas of the Gastroenteropancreatic System: from Morphology to Proliferation and back
    La Rosa, Stefano
    Sessa, Fausto
    ENDOCRINE PATHOLOGY, 2014, 25 (02) : 193 - 198
  • [15] Poorly Differentiated Neuroendocrine Carcinoma of the Sigmoid Tract in Long-Standing Ulcerative Colitis: Report of a Case and Review of the Literature
    Bolzacchini, Elena
    Chini, Claudio
    Cortelezzi, Claudio Camillo
    Vallini, Ilaria
    Pinotti, Graziella
    La Rosa, Stefano
    Uccella, Silvia
    INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY, 2018, 26 (05) : 479 - 483
  • [16] Pulmonary and extrapulmonary poorly differentiated large cell neuroendocrine carcinomas - Diagnostic and prognostic features
    Faggiano, Antongiulio
    Sabourin, Jean-Cristophe
    Ducreux, Michel
    Lumbroso, Jean
    Duvillard, Pierre
    Leboulleux, Sophie
    Dromain, Clarisse
    Colao, Annamaria
    Schlumberger, Martin
    Baudin, Eric
    CANCER, 2007, 110 (02) : 265 - 274
  • [17] Cisplatin and Etoposide as First-line Chemotherapy for Poorly Differentiated Neuroendocrine Carcinoma of the Hepatobiliary Tract and Pancreas
    Iwasa, Satoru
    Morizane, Chigusa
    Okusaka, Takuji
    Ueno, Hideki
    Ikeda, Masafumi
    Kondo, Shunsuke
    Tanaka, Tsutomu
    Nakachi, Kohei
    Mitsunaga, Shuichi
    Kojima, Yasushi
    Hagihara, Atsushi
    Hiraoka, Nobuyoshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (04) : 313 - 318
  • [18] Poorly differentiated neuroendocrine carcinomas - Characteristics, treatments and outcomes from a population-based cohort discussed in our ENETS-CoE institute
    Benini, L.
    Spada, F.
    Gervaso, L.
    Borghesani, M.
    Rubino, M.
    Cella, C. A.
    Algeri, L.
    Pisa, E.
    Boselli, S.
    Fazio, N.
    JOURNAL OF NEUROENDOCRINOLOGY, 2023, 35 : 63 - 63
  • [19] Neuroendocrine carcinomas of the gastrointestinal tract: Morphology, molecular pathology, cellular origin
    Jesinghaus, Moritz
    PATHOLOGIE, 2024, 45 (SUPPL1): : 8 - 13
  • [20] Survival outcomes of poorly differentiated colorectal carcinoma variants: Insights from a single teaching institute☆
    Xu, Zhengfan
    Theisen, Brian K.
    Chang, Qing
    Schultz, Daniel
    Ahsan, Beena U.
    HUMAN PATHOLOGY, 2024, 154